Replidyne terminates Phase III bronchitis trial

Replidyne took this action to conserve its cash assets and support initiatives that include pursuing strategic transactions and maintaining its research programs.

The acute exacerbation of chronic bronchitis study is one in a group of four clinical trials, including two in community-acquired pneumonia and one in acute bacterial sinusitis, recommended as a way forward by the FDA for a new drug application submission for faropenem to treat these three adult community respiratory tract infections. Replidyne has not initiated the other three trials, and consistent with prior guidance, further faropenem development will depend on Replidyne securing a partner for the program.

Kenneth Collins, Replidyne’s president and CEO, said: “In the interest of conserving our financial position, we have made a difficult decision to discontinue enrollment in this faropenem trial. This decision reflects our sense of urgency and the belief that in today’s environment available cash assets broaden the scope of potential partnering and strategic options.”